Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from complications from cancer treatment to nutritional disorders and diseases brought on by viral infections and immune malfunction.
Disease targets include large patient populations with inflammatory bowel diseases (ulcerative colitis and Crohn’s), digestive disorders (exocrine pancreatic insufficiency in cystic fibrosis patients), and the COVID-19 pandemic (acute and long-haul COVID-related GI infections).
IN THE NEWS
|
Jan 13, 2022
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
|
|
Jan 07, 2022
First Wave BioPharma Announces Further Adjournment of Annual Meeting
|
|
Jan 06, 2022
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
|
